Etern Biopharma (Shanghai) Co. Ltd. has divulged transcriptional coactivator YAP1 and TAZ/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer.

Sichuan Haisco Pharmaceutical Co. Ltd. has identified phosphodiesterase PDE3 and phosphodiesterase PDE4 inhibitors reported to be useful for the treatment of chronic obstructive pulmonary disease (COPD) and asthma.

Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have synthesized benzimidazole derivatives acting as serine/threonine-protein kinase SIK2 (QIK) and/or SIK1 (SNF1LK) and/or SIK3 (QSK) inhibitors reported to be useful for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, inflammatory bowel disease, atherosclerosis, type 2 diabetes and glomerulonephritis, among others.

Jiangsu Yayo Biotechnology Co. Ltd. has disclosed ATR kinase inhibitors reported to be useful for the treatment of cancer.

Gasherbrum Bio Inc. has described glucagon-like peptide 1 receptor (GLP1R) agonists reported to be useful for the treatment of type 2 diabetes, dyslipidemia, hyperglycemia, hypertension, obesity, stroke, myocardial infarction and gout, among others.

Shanghai Apeiron Biotechnology Co. Ltd. has divulged GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Redx Pharma plc has identified Rho kinase 1 (ROCK 1; p160-ROCK) and/or rho kinase 2 (ROCK 2; ROCKα) inhibitors reported to be useful for the treatment of cancer, fibrosis, autoimmune, inflammatory and neurological disorders.

Silexon Intelligent Technology Co. Ltd. has synthesized heterocyclic compounds acting as mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer and viral infections.

Shanghai Haihe Biopharma Co. Ltd. has disclosed phosphonic acid derivatives and their prodrugs reported to be useful for the treatment of cancer and infections.

Aurigene Oncology Ltd. has described substituted bicyclic heterocycles acting as mucosa associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors reported to be useful for the treatment of cancer, rheumatoid arthritis, ulcerative colitis, asthma, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), psoriasis and systemic lupus erythematosus (SLE), among others.